Allergy Diagnostics Market: as allergic disease prevalence keeps outrunning the supply of specialist allergists, every additional site that can run a validated specific-IgE panel now converts unmeasured symptoms into billable diagnostic volume, so testing is spreading from dedicated allergy clinics into primary care and hospital stewardship programmes, and competitive advantage is shifting toward platforms that can prove component-level precision rather than those that simply process the most samples.

The global allergy diagnostics market size was USD 6.24 Billion in 2025 and is expected to register a revenue CAGR of 10.8% during the forecast period. Market revenue growth is driven by factors such as the rising global prevalence of allergic disease, the expanding clinical indication for allergy testing beyond specialist evaluation into primary care, and the institutional adoption of drug allergy delabelling programmes. The first driving factor is the scale of allergic disease relative to diagnosed and tested patients. The World Allergy Organization estimates that allergic diseases affect 20 to 30% of the world population, and the American Academy of Allergy, Asthma and Immunology reports that approximately 50 to 60 million Americans have allergic rhinitis, representing a testing addressable population substantially larger than the population currently receiving diagnostic-guided care. The second driving factor is the expansion of allergy testing access through laboratory automation and point-of-care platforms. In vitro specific IgE testing accounts for approximately 46% of total 2025 market revenue across hospital, reference laboratory, and specialist clinic settings, reflecting how much of current volume already runs through automated rather than manual testing formats. The third driving factor is the institutional adoption of penicillin allergy delabelling programmes in hospital antimicrobial stewardship. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single validated diagnostic platform accumulates additional allergen components over time, which converts one laboratory's testing menu into a steadily widening source of billable volume without acquiring a new client account. Once a laboratory adopts a component-resolved diagnostics platform, each additional validated allergen component adds a new billable test to the existing patient relationship without requiring a new referral pathway or new capital equipment, so testing menu depth compounds in value as the platform's component library grows around the same installed analyser base. As a result, demand and revenue share are concentrating around platforms that hold the broadest validated component menus, and the forecast tilts toward laboratories running multiplex component-resolved panels rather than single-allergen extract testing alone. For instance, in July 2025, Siemens Healthineers introduced a new dedicated immunoassay platform built specifically to reduce turnaround time for allergy-specific IgE testing, one of a widening set of platform-level investments aimed at converting general hospital laboratories into allergy testing sites without requiring a dedicated allergy reference laboratory. These are some of the key factors driving revenue growth of the market.

Because payer prior authorisation requirements for specific IgE panels exceeding three to five allergens per request and low per-test reimbursement rates at ambulatory care settings create a financial incentive for primary care physicians to manage allergic symptoms empirically, many patients never reach diagnostic-guided allergy evaluation at all.

Under-utilisation in hospital settings is a second constraint, because a majority of patients labelled penicillin-allergic in hospital records have never undergone formal allergy challenge testing to confirm their status, which reflects structural underuse of confirmatory testing even where the clinical and cost case for it is strong.

Specialist capacity is a third constraint, since the allergist workforce has not grown in proportion to allergic disease prevalence, so testing demand increasingly depends on primary care and telehealth channels adopting diagnostic protocols historically confined to specialist clinics.

These factors substantially limit allergy diagnostics market growth over the forecast period.

The clearest driver of demand is the shift from whole-allergen extract testing to allergen component-level IgE quantification, which resolves a diagnostic ambiguity that extract testing cannot. Conventional whole-extract IgE testing cannot distinguish clinically significant primary sensitisation, such as true peanut allergy, from clinically minor cross-reactive sensitisation driven by pollen-food syndrome, so component-resolved testing works only where the underlying allergen has been broken into its individual molecular components, and immunotherapy prescribing increasingly requires that level of precision before treatment begins. The World Allergy Organization estimates that allergic diseases affect 20 to 30% of the world population, and Thermo Fisher Scientific's ImmunoCAP platform is documented in more than 6,000 peer-reviewed publications, giving component-resolved testing a clinical evidence base that supports its premium price over extract-level testing. In March 2023, Thermo Fisher Scientific extended its ImmunoCAP platform from whole-allergen extract measurement to allergen molecular component quantification, enabling allergists to distinguish primary peanut sensitisation from cross-reactive pollen-driven peanut IgE that produces false-positive extract results. The effect on the market is that testing revenue per patient rises as laboratories add component-level assays to their existing IgE testing menu without acquiring new patient volume. These are some of the key factors driving revenue growth of the market.

The second driver is the clinical and financial case for penicillin allergy delabelling built on formal specific-IgE testing and supervised oral challenge. Antimicrobial stewardship programmes work only if clinicians can trust a patient's documented allergy status, and a mislabelled penicillin allergy forces the use of broader-spectrum antibiotics that carry worse outcomes, so hospitals with active stewardship mandates have a direct financial and clinical reason to fund systematic delabelling testing. The 2023 JAMA Internal Medicine study documenting that a majority of hospital patients labelled penicillin-allergic had never undergone formal allergy challenge testing established the scale of this gap and gave stewardship committees a citable evidence base for funding routine delabelling protocols. In January 2024, ALK-Abelló announced a telehealth partnership offering remote allergy testing consultation paired with at-home blood collection for specific IgE testing, expanding diagnostic access to patients in areas without a local specialist. The effect on the market is a new institution-initiated demand channel for penicillin-specific IgE testing that is funded by hospital stewardship budgets rather than by patient-initiated specialist referral. These are some of the key factors driving revenue growth of the market.

The World Allergy Organization estimates that 20 to 30% of the world's population has an allergic disease. Testing that reaches even a fraction more of that population through primary care and hospital stewardship channels represents a structurally larger addressable market than specialist-only testing ever could.

The third driver is the early integration of computerised sensitisation profiling tools that combine multiplex component-resolved results with patient clinical history. Interpreting a component-resolved diagnostics panel requires correlating dozens of individual allergen-component values against a patient's symptom history, so software that automates this correlation reduces the specialist time needed per patient and makes component-resolved testing practical to deploy outside dedicated allergy centres. In July 2024, the Castile and León regional health authority in Spain partnered with Aiforia Technologies for AI-assisted diagnostic image analysis, part of a broader regional trend toward AI-assisted diagnostic interpretation that is beginning to extend into allergy sensitisation profiling. The effect on the market is that component-resolved testing becomes accessible to general hospital laboratories and primary care networks that lack in-house allergist interpretation capacity. These are some of the key factors driving revenue growth of the market.

However, the allergy diagnostics market faces severe adoption constraints from limited reimbursement for comprehensive testing panels and the persistent gap between allergic disease prevalence and diagnostic testing utilisation.

Because payer prior authorisation requirements for specific IgE panels exceeding three to five allergens per request combine with low per-test reimbursement rates at ambulatory care settings, primary care physicians face a direct financial incentive to manage allergic symptoms empirically with antihistamines and nasal corticosteroids rather than order diagnostic-guided evaluation, and this incentive persists regardless of how much component-resolved testing improves clinical precision.

Under-utilisation in hospital settings compounds this, because the JAMA Internal Medicine finding that most penicillin-labelled patients have never been formally tested shows that even where testing infrastructure already exists inside a hospital, workflow and awareness barriers keep it from being ordered routinely.

Specialist capacity is the third constraint, since allergist training pipelines have not expanded in proportion to allergic disease prevalence, so testing growth depends on primary care and telehealth clinicians adopting diagnostic protocols and interpretation support tools that were originally built for specialist use only.

These factors substantially limit allergy diagnostics market growth over the forecast period.

Based on product, the global allergy diagnostics market is segmented into instruments, consumables, and software. In vitro specific IgE testing consumables hold the largest revenue share, because automated IgE quantification is now the default confirmatory test ordered after a positive skin prick screen at most hospital and reference laboratories, which suits a market where testing volume tracks laboratory throughput more than any single diagnostic breakthrough. Component-resolved diagnostics software and sensitisation-profiling tools remain a smaller category today but are cheaper to add to an existing platform than new instrumentation, and they cannot yet match the installed base of conventional extract-level testing. Software is expected to register the fastest revenue growth rate in the global allergy diagnostics market over the forecast period, driven by the early deployment of AI-assisted sensitisation profiling tools such as the Castile and León regional health authority's 2024 partnership with Aiforia Technologies, which is why other European academic allergy centres are evaluating similar computerised interpretation systems.

Component-resolved diagnostics test type is expected to account for a significantly large revenue share in the global allergy diagnostics market during the forecast period

Based on test type, the global allergy diagnostics market is segmented into in vitro specific IgE, in vivo skin prick testing, component-resolved diagnostics, and provocation and food challenge tests. In vitro specific IgE testing holds the largest revenue share, because it can be run on stored serum samples without requiring a specialist visit or exposing the patient to a live allergen, which suits reference laboratories serving primary care referrals at scale. Component-resolved diagnostics is expected to register the fastest revenue growth rate in the global allergy diagnostics market over the forecast period, driven by immunotherapy prescribers requiring component-level confirmation before starting treatment, which is why Thermo Fisher Scientific's ImmunoCAP allergen component menu continues to expand beyond its original extract-level test portfolio.

Based on allergen type, the global allergy diagnostics market is segmented into inhaled aeroallergens, food allergens, and drug and contact allergens. Food allergens hold the largest revenue share, because the American Academy of Allergy, Asthma and Immunology's estimate of approximately 32 million Americans with food allergies drives high per-patient testing volume across peanut, tree nut, milk, egg, and shellfish component panels, which ties directly back to the diagnostic precision gains described in the market's primary demand driver. Drug and contact allergens are expected to register the fastest revenue growth rate in the global allergy diagnostics market over the forecast period, driven by hospital antimicrobial stewardship programmes funding penicillin-specific IgE testing at scale, which is why ALK-Abelló's telehealth-enabled testing partnership is expanding drug allergy testing access beyond specialist allergy clinics.

Based on regional analysis, the allergy diagnostics market in North America accounted for largest revenue share in 2025. The United States leads because the American Academy of Allergy, Asthma and Immunology's reported burden of allergic rhinitis, food allergy, and asthma sustains high testing referral volume, and because Thermo Fisher Scientific, Siemens Healthineers, Abbott Laboratories, and Hycor Biomedical all maintain their primary commercial and regulatory presence in the US market. Thermo Fisher Scientific's Specialty Diagnostics segment, which encompasses ImmunoCAP allergy testing, accounted for 10% of the company's USD 44.56 Billion FY2025 total revenue, anchoring a domestic testing infrastructure large enough to sustain multiple competing allergy IVD platforms simultaneously. The concentration of allergy IVD manufacturing and regulatory activity in the country also means new component-resolved diagnostics assays are typically validated in the United States first, before expanding to other regulatory jurisdictions.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, and the United Kingdom represent the three largest national allergy diagnostics markets within Europe. European academic allergy centres have been early adopters of molecular component-resolved diagnostics, and the Castile and León regional health authority's 2024 partnership with Aiforia Technologies for AI-assisted diagnostic interpretation illustrates how European public health systems are beginning to formalise AI-assisted allergy testing workflows ahead of similar adoption elsewhere. The result is steady rather than rapid growth, shaped more by national health system procurement cycles than by underlying patient demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. China and Japan represent the two largest national markets within the region, driven by rising urban allergic disease prevalence and expanding private hospital laboratory infrastructure. Japan is the earlier-launch market for advanced component-resolved diagnostics platforms in the region, which leaves more room for growth than in the already laboratory-saturated North American market.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national allergy diagnostics markets within the region, with private reference laboratory networks driving early adoption of automated specific IgE testing platforms. The ongoing Iran-US sanctions and the resulting Strait of Hormuz shipping disruption have raised freight and import costs for the reagents and precision instrumentation that Latin American reference laboratories depend on, an effect expected to run through 2026 and slow allergy diagnostics adoption beyond Brazil's and Mexico's main urban centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial markets within the region. Saudi Arabia's expanding private hospital laboratory network and the UAE's regional reference laboratory hubs represent the primary investment centres for allergy diagnostics adoption. Saudi Arabia is the most established market on the continent, while the Gulf states outside it are still building the specialist and laboratory capacity needed to support component-resolved diagnostics at scale.